-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NpzhxTdqleV4XpfEVicY0A74OwwOByuRyxMQH8Z7FE0VTHwyFF8jGdWIrq+AzlMl 1djfUEaKvisNvNPUCh1uRA== 0001123292-09-000260.txt : 20090303 0001123292-09-000260.hdr.sgml : 20090303 20090303151843 ACCESSION NUMBER: 0001123292-09-000260 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090223 FILED AS OF DATE: 20090303 DATE AS OF CHANGE: 20090303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FALBERG KATHRYN E CENTRAL INDEX KEY: 0001206977 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 09651391 BUSINESS ADDRESS: STREET 1: 3400 CENTRAL EXPRESSWAY CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: 4087332020 MAIL ADDRESS: STREET 1: 3400 CENTRAL AVENUE CITY: SANTA CLARA STATE: CA ZIP: 95051 3 1 edgar.xml PRIMARY DOCUMENT X0203 3 2009-02-23 0 0000907654 ARCA biopharma, Inc. ABIO 0001206977 FALBERG KATHRYN E 52 PIEDMONT ROAD LARKSPUR CA 94939 0 1 0 0 CFO and COO Common Stock 21000 D Patrick Wheeler, attorney in fact 2009-03-03 EX-24 2 kfalbergpoa.htm

ARCA BIOPHARMA, INC.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Christopher Ozeroff, Patrick Wheeler and Brian Selby, signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

(1) execute and file for and on behalf of the undersigned, in the undersigned’s name, place and stead, in any and all capacities, all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the United States Securities and Exchange Commission as a result of the undersigned’s ownership of or transactions in securities of ARCA biopharma, Inc. (the “Company”);

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file any such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, and in the best interest of, or legally required by, the undersigned.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of February 26, 2009.

s/Kathryn Falberg

Signature

Kathryn Falberg

Print Name

-----END PRIVACY-ENHANCED MESSAGE-----